Nicholas E Houstis1, Aaron S Eisman1, Paul P Pappagianopoulos1, Luke Wooster1, Cole S Bailey1, Peter D Wagner2, Gregory D Lewis3. 1. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston (N.E.H., A.S.E., P.P.P., L.W., C.S.B., G.D.L.). 2. School of Medicine, University of California, San Diego (P.D.W.). 3. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston (N.E.H., A.S.E., P.P.P., L.W., C.S.B., G.D.L.) glewis@partners.org.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with a pressing shortage of therapies. Exercise intolerance is a cardinal symptom of HFpEF, yet its pathophysiology remains uncertain. METHODS: We investigated the mechanism of exercise intolerance in 134 patients referred for cardiopulmonary exercise testing: 79 with HFpEF and 55 controls. We performed cardiopulmonary exercise testing with invasive monitoring to measure hemodynamics, blood gases, and gas exchange during exercise. We used these measurements to quantify 6 steps of oxygen transport and utilization (the O2 pathway) in each patient with HFpEF, identifying the defective steps that impair each one's exercise capacity (peak Vo2). We then quantified the functional significance of each O2 pathway defect by calculating the improvement in exercise capacity a patient could expect from correcting the defect. RESULTS: Peak Vo2 was reduced by 34±2% (mean±SEM, P<0.001) in HFpEF compared with controls of similar age, sex, and body mass index. The vast majority (97%) of patients with HFpEF harbored defects at multiple steps of the O2 pathway, the identity and magnitude of which varied widely. Two of these steps, cardiac output and skeletal muscle O2 diffusion, were impaired relative to controls by an average of 27±3% and 36±2%, respectively (P<0.001 for both). Due to interactions between a given patient's defects, the predicted benefit of correcting any single one was often minor; on average, correcting a patient's cardiac output led to a 7±0.5% predicted improvement in exercise intolerance, whereas correcting a patient's muscle diffusion capacity led to a 27±1% improvement. At the individual level, the impact of any given O2 pathway defect on a patient's exercise capacity was strongly influenced by comorbid defects. CONCLUSIONS: Systematic analysis of the O2 pathway in HFpEF showed that exercise capacity was undermined by multiple defects, including reductions in cardiac output and skeletal muscle diffusion capacity. An important source of disease heterogeneity stemmed from variation in each patient's personal profile of defects. Personalized O2 pathway analysis could identify patients most likely to benefit from treating a specific defect; however, the system properties of O2 transport favor treating multiple defects at once, as with exercise training.
BACKGROUND:Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with a pressing shortage of therapies. Exercise intolerance is a cardinal symptom of HFpEF, yet its pathophysiology remains uncertain. METHODS: We investigated the mechanism of exercise intolerance in 134 patients referred for cardiopulmonary exercise testing: 79 with HFpEF and 55 controls. We performed cardiopulmonary exercise testing with invasive monitoring to measure hemodynamics, blood gases, and gas exchange during exercise. We used these measurements to quantify 6 steps of oxygen transport and utilization (the O2 pathway) in each patient with HFpEF, identifying the defective steps that impair each one's exercise capacity (peak Vo2). We then quantified the functional significance of each O2 pathway defect by calculating the improvement in exercise capacity a patient could expect from correcting the defect. RESULTS: Peak Vo2 was reduced by 34±2% (mean±SEM, P<0.001) in HFpEF compared with controls of similar age, sex, and body mass index. The vast majority (97%) of patients with HFpEF harbored defects at multiple steps of the O2 pathway, the identity and magnitude of which varied widely. Two of these steps, cardiac output and skeletal muscle O2 diffusion, were impaired relative to controls by an average of 27±3% and 36±2%, respectively (P<0.001 for both). Due to interactions between a given patient's defects, the predicted benefit of correcting any single one was often minor; on average, correcting a patient's cardiac output led to a 7±0.5% predicted improvement in exercise intolerance, whereas correcting a patient's muscle diffusion capacity led to a 27±1% improvement. At the individual level, the impact of any given O2 pathway defect on a patient's exercise capacity was strongly influenced by comorbid defects. CONCLUSIONS: Systematic analysis of the O2 pathway in HFpEF showed that exercise capacity was undermined by multiple defects, including reductions in cardiac output and skeletal muscle diffusion capacity. An important source of disease heterogeneity stemmed from variation in each patient's personal profile of defects. Personalized O2 pathway analysis could identify patients most likely to benefit from treating a specific defect; however, the system properties of O2 transport favor treating multiple defects at once, as with exercise training.
Authors: Mark J Haykowsky; Peter H Brubaker; Jerry M John; Kathryn P Stewart; Timothy M Morgan; Dalane W Kitzman Journal: J Am Coll Cardiol Date: 2011-07-12 Impact factor: 24.094
Authors: Fabio Esposito; Odile Mathieu-Costello; Ralph Shabetai; Peter D Wagner; Russell S Richardson Journal: J Am Coll Cardiol Date: 2010-05-04 Impact factor: 24.094
Authors: Bishnu P Dhakal; Rajeev Malhotra; Ryan M Murphy; Paul P Pappagianopoulos; Aaron L Baggish; Rory B Weiner; Nicholas E Houstis; Aaron S Eisman; Stacyann S Hough; Gregory D Lewis Journal: Circ Heart Fail Date: 2014-10-24 Impact factor: 8.790
Authors: Wojciech Kosmala; Aleksandra Rojek; Monika Przewlocka-Kosmala; Andrzej Mysiak; Bozena Karolko; Thomas H Marwick Journal: J Am Coll Cardiol Date: 2016-02-16 Impact factor: 24.094
Authors: R Boushel; I Ara; E Gnaiger; J W Helge; J González-Alonso; T Munck-Andersen; H Sondergaard; R Damsgaard; G van Hall; B Saltin; J A L Calbet Journal: Acta Physiol (Oxf) Date: 2014-03-17 Impact factor: 6.311
Authors: Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald Journal: JAMA Date: 2013-03-27 Impact factor: 56.272
Authors: Barry A Borlaug; Kevin J Anstrom; Gregory D Lewis; Sanjiv J Shah; James A Levine; Gabe A Koepp; Michael M Givertz; G Michael Felker; Martin M LeWinter; Douglas L Mann; Kenneth B Margulies; Andrew L Smith; W H Wilson Tang; David J Whellan; Horng H Chen; Victor G Davila-Roman; Steven McNulty; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield Journal: JAMA Date: 2018-11-06 Impact factor: 56.272
Authors: Jennifer E Ho; Emily K Zern; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Giovanna A Zampierollo; Petr Jarolim; Paul P Pappagianopoulos; Rajeev Malhotra; Matthew Nayor; Gregory D Lewis Journal: Circulation Date: 2019-05-28 Impact factor: 29.690
Authors: Satyam Sarma; Douglas Stoller; Joseph Hendrix; Erin Howden; Justin Lawley; Sheryl Livingston; Beverley Adams-Huet; Courtney Holmes; David S Goldstein; Benjamin D Levine Journal: Circ Heart Fail Date: 2020-03-13 Impact factor: 8.790
Authors: Benjamin W Van Tassell; Cory R Trankle; Justin M Canada; Salvatore Carbone; Leo Buckley; Dinesh Kadariya; Marco G Del Buono; Hayley Billingsley; George Wohlford; Michele Viscusi; Claudia Oddi-Erdle; Nayef A Abouzaki; Dave Dixon; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate Journal: Circ Heart Fail Date: 2018-08 Impact factor: 8.790